RNS Number: 3740 V Diurnal Group PLC 02 December 2019 2 December 2019. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that it has issued 30,000 new ordinary shares of 5 pence each as a result of an exercise of options under the Company's Long Term Incentive Plan.. Founded in 2004, Diurnal...
RNS Number: 2374 V Diurnal Group PLC 02 December 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2373 V Diurnal Group PLC 02 December 2019 02 December 2019. US submission follows successful launch in Europe. The pathway is based on a development programme for Alkindi ®, including a study to demonstrate bioequivalence with the US reference product, as well as a safety evaluation and tolerability extension study in Europe, which provides...
End of Announcement- EQS News Service.
RNS Number: 2482 U Diurnal Group PLC 21 November 2019 21 November 2019. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. RNS is approved by the Financial...
Diurnal's primary focus remains on progressing Chronocort ® and Alkindi ®, our two lead products, which are potentially valuable treatment options with a combined opportunity of over $3 bn for diseases resulting from cortisol deficiency in the US and Europe.. Diurnal remains on track to submit two key regulatory filings during Q4 2019, namely a Marketing...
RNS Number: 9755 T Diurnal Group PLC 20 November 2019 20 November 2019. Potential to be the first effective oral native testosterone treatment in a $4.8 bn global market. The estimated $4.8 billion market in US and Europe for testosterone-based products for the treatment of hypogonadism is dominated by topically-available products, which have compliance...
Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that the Remuneration Committee has determined the proportion of options over ordinary shares of 5 pence each in Diurnal previously granted under the Diurnal Group plc Long Term Incentive Plan to Directors of the Company that are...
End of Announcement- EQS News Service.
RNS Number: 6211 Q Diurnal Group PLC 21 October 2019 21 October 2019. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that further to the Directors' dealings announced today, the new Ordinary Shares were issued from the Company's Employee Benefit Trust scheme. 1,786,439 new Ordinary...
RNS Number: 5835 Q Diurnal Group PLC 21 October 2019 21 October 2019. Martin Whitaker, Chief Executive Officer, exercised options over 424,500 ordinary shares of £0.05 each at a price of 0.2 p pence per Ordinary Share and sold 230,152 Ordinary Shares at a price of 26 pence per ordinary share in order to fund the exercise price, income taxes, and to satisfy market...
The Company's AGM will be held at 11.00 am at the offices of FTI Consulting LLP, 200 Aldersgate, Aldersgate Street, London, EC1A 4 HD on Thursday 21 November 2019.. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including...
Diurnal Group Plc (DNL.L) Announced, in its audited results for the year ended 30 June 2019, that the revenue rose to £1.04
million from £0.073 million posted in the same period preceding year. The company’s loss before tax
stood at £514.39 million, compared to loss of £16.91 million reported in the previous year. The basic
loss per share stood at 19.7p compared to loss per share of 26.8p reported in the previous year. The
company’s cash and equivalents stood at £9.15 million.
·Successful launch of Alkindi ® in the UK as the first specifically developed and licensed replacement therapy for paediatric adrenal insufficiency. ·Alkindi ® pricing agreed in Germany, Italy, Austria, Sweden, Norway, Denmark and Iceland. ·Progress in the rest of world with Alkindi ® Marketing Authorisation Application submission in Israel and grant of...
Martin Whitaker, Chief Executive Officer, sold 44,810 Ordinary Shares at a price of 37 pence per Ordinary Share and his ISA purchased 44,810 Ordinary Shares at a price of 37.1 pence per Ordinary Share.. Additionally, Martin Whitaker purchased a total of 15,104 Ordinary Shares at 38 pence per share, to be held in pension schemes for the beneficial interest of his...
RNS Number: 9212 H Diurnal Group PLC 05 August 2019 5 August 2019. Grant of Deferred Share Awards. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces the following deferred bonus share awards over ordinary shares of 5 pence in Diurnal were granted under the Diurnal Group plc Long Term...
RNS Number: 9265 G Diurnal Group PLC 26 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8272 E Diurnal Group PLC 08 July 2019 8 July 2019. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces the issue and allotment of 11,884 ordinary shares of £0.05 to John Goddard, Non-Executive Director of the Company, as part of a pre-existing arrangement whereby he receives...
Bid
--
-
Ask
- High-
- OPEN-
- VOL-
- MKT CAP-m
- LOW-
- CLOSE-
- AVG VOL-
- SHARES IN ISSUE84.53M
Company Profile
Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.
Classification
| Market Indices | - |
Locations
| HQ | 1 Callaghan Square Cardiff CF10 5BT |